Mar 14, 2019 / 03:15PM GMT
Gena Wang - Barclays Bank PLC, Research Division - Research Analyst
Good morning, everyone. My name is Gena Wang. I'm the [SME-cap] biotech analyst at Barclays. It is my great pleasure to introduce our next speakers, Charlie Albright, Chief Scientific Officer from Editas. Also together with us, we have Cindy Collins, Interim CEO with us for Q&A session.
Charles Albright - Editas Medicine, Inc. - Chief Scientific Officer
Thank you, Gena. It's a pleasure to be here. Developing innovative medicines with a new technology is an area with great promise. It's also an area with some risk. And for that reason, I'll be making forward-looking statements, and I encourage you to read the slide at your convenience.
Our mission at Editas is to take the incredible power of CRISPR gene editing and turn it into transformational medicines. I want to update you today on where we are on that -- on accomplishing that mission, and I want to start by the progress we've made in 2018.
Certainly, one of the largest things we did last year was to get filed and have
Editas Medicine Inc at Barclays Global Healthcare Conference Transcript
Mar 14, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers